[Prognostic changes in juvenile abdominal non-Hodgkin's lympomas (NHL)].
From 1964-1978 primary non-Hodgkin's lymphoma was diagnosed and treated in 15 children (13 boys and 2 girls). In the 10 patients treated up to 1974, median survival was only 4 months (the longest being 16 months). Since 1974 all such patients have been put on high-dose combined chemotherapy as early as possible. Of 5 children thus treated, 3 have survived for 60, 26 and 11 months respectively and are still alive disease-free. The other two died after 4 1/2 and 5 1/2 months respectively: both had very widespread disease at diagnosis and chemotherapy was delayed by postoperative complications. The 4 most recent tumors have been classified immunologically: 3 were of the B-cell type and exhibited the classic "Burkitt-type" morphology. Two of these patients are alive and well. Although so small a patient material allows no firm conclusions, the authors feel that early intensive chemotherapy may be curative even in this poor-prognosis group of intraabdominal non-Hodgkin's lymphoma.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin
Prognostischer Wandel bei den abdominalen Nicht-Hodgkin-Lymphomen (NHL) im Kindesalter.